Clinical Outcomes in Hereditary Cancer
Compare the clinical characteristics and post-surgical outcomes (overall survival)of
pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations
in BRCA1 or BRCA2 .
Compare the clinical characteristics and outcomes (time to progression) of breast cancer
patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2
receiving paclitaxel chemotherapy for metastatic disease.
Observational Model: Cohort, Time Perspective: Retrospective
The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.
Mark Robson, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|